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Abstract
Invasion of human red blood cells by Plasmodium merozoites is vital for replication and survival of the parasite and, as such,
is an attractive target for therapeutic intervention. Merozoite invasion is mediated by specific interactions between parasite
ligands and host erythrocyte receptors. The P. vivax Duffy-binding protein (PvDBP) is heavily dependent on the interaction
with the human Duffy blood group antigen/receptor for chemokines (DARC) for invasion. Region II of PvDBP contains many
allelic polymorphisms likely to have arisen by host immune selection. Successful vaccine development necessitates a deeper
understanding of the role of these polymorphisms in both parasite function and evasion of host immunity. A 3D structure of
the homologous P. knowlesi DBP predicts that most variant residues are surface-exposed, including N417K, which is a
dimorphic residue change that has previously been shown to be part of a linked haplotype that alters DBP sensitivity to
inhibitory antibody. In natural isolates only two residues are found at this site, asparagine (N) and lysine (K). Site-directed
mutagenesis of residue 417 was used to create a panel of 20 amino acid variants that were then examined for their binding
phenotype and response to immune sera. Our results suggest that the observed dimorphism likely arose due to both
structural requirements and immune selection pressure. To our knowledge, this is the first exhaustive examination of this
kind of the role of a single amino acid residue in antigenic character and binding ability. Our results demonstrate that a
single amino acid substitution can dramatically alter both the ability of the PvDBP to bind to human erythrocytes and its
antigenic character.
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Introduction
Plasmodium vivax is responsible for 70–80 million cases of clinical
malaria annually and has a wide distribution that causes more
than 50% of malaria cases outside of Africa [1]. Increasing reports
of parasite drug resistance as well as cases of severe clinical disease
due to P. vivax emphasize the need for better prevention and
treatment strategies [2–5]. The Duffy binding protein (DBP) is a
cysteine rich protein located in the micronemes of the P. vivax
merozoites [6,7]. It is believed to be released from the micronemes
during initial attachment of the merozoite to the erythrocyte and is
required for junction formation which is necessary to complete the
invasion process [8]. DBP is an attractive vaccine target because of
its nearly absolute requirement for invasion of host erythrocytes
and because antibodies that recognize this molecule correlate with
protection against infection [9,10]. DBP contains the prototypical
Duffy-binding ligand (DBL) domain or region II, which is a
cysteine-rich region (12 consensus cysteines) responsible for
receptor recognition in a wide variety of parasite cytoadhesion
proteins [7]. A site critical for erythrocyte receptor (Duffy antigen/
receptor for chemokines, or DARC) recognition has been mapped
to an area between cysteines 4 and 7 of the DBL domain [11–13].
Interestingly, this is also the most highly polymorphic region of the
entire open reading frame with a high ratio of nonsynonymous to
synonymous polymorphisms, suggesting positive selection indica-
tive of immune pressure [14–16]. In a similar manner,
examination of the non-homologous proteins Influenza hemagglu-
tinin (HA) and Plasmodium apical membrane antigen 1 (AMA-1)
reveals a pattern of polymorphisms located adjacent to and
surrounding their putative receptor binding sites. A consensus
viewpoint interprets these substitutions as making it more difficult
for host inhibitory antibodies, elicited by previous exposure to the
pathogen, to recognize new variant epitopes and block the
interaction between the pathogen ligand and the host receptor
[17–22]. We hypothesize that the same mechanism of immune
evasion operates to drive allelic diversity of DBP.
In previous studies we analyzed the variant alleles of field
isolates from Papua New Guinea and determined that several
polymorphisms (N417K, W437R, I503K) formed a linked
haplotype [23]. This haplotype was shown to be important in
determining the antigenic character and sensitivity of DBP to
antibody inhibition. DBP containing 417K, 437R and 503K were
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417N, 437W and 503I were sensitive to inhibition. This result
indicated that N417K forms part of an important haplotype that
alters the antigenic character of DBP while other data supports
that the N417K variation has special significance. Mapping of
N417K onto a P. vivax DBP homology model based on the P.
knowlesi DBPa crystal structure reveals that this residue is
immediately adjacent to a motif identified by mutational analysis
to be important for DARC receptor recognition [24,25]. In
addition, variation at residue 417 is limited to either N or K in all
field isolates examined. Therefore, the objective of this research is
to provide additional experimental rationale to account for the
limited dimorphism at this residue. We hypothesize that functional
requirements limit the type of substitutions at this site because
other amino acids will interfere with the binding of the parasite
ligand to the erythrocyte receptor. Alternatively, we hypothesize
that positive immune pressure selects for compatible amino acids
that also alter antigenic character in functionally important
residues. Our results demonstrate that single amino acid
substitutions at this site have a significant impact on the antigenic
character of the PvDBP but variation is limited by functional
constraints to bind the human erythrocyte receptor.
Results
Our previous study of genetic analysis of pvdbp in clinical isolates
has shown that variation at residue 417 is often linked to residues
437 and 503 [23]. We updated this analysis by examining 292
available PvDBPII sequences (Table 1). Residues 417 and 437
were linked 94.7% of the time, while residues 417 and 503 were
linked 70.5% of the time. Analysis of this dataset indicated a total
of 55 polymorphic sites with 50 dimorphisms, 4 trimorphisms and
1 site with four alternate residues.
We analyzed the binding phenotype of variant constructs
containing each of the 20 amino acids at site 417 using an in vitro
COS7 cell assay for DBP-erythrocyte binding function (Fig. 1).
Nine of the constructs bound significantly less than the naturally
occurring residues, N and K (p,0.05). Most of these residues were
nonpolar although Y was also a poor binder. Nine of the variants,
including two nonpolar residues (A and G), were not significantly
lower than the naturally occurring residues in their binding
phenotype (p.0.05) and did not bind to Duffy negative cells. We
further analyzed these nine ‘normal binding’ variants for their
inhibition phenotypes using polyclonal rabbit sera raised against
the Sal I strain DBPII containing N at the 417 site (Fig. 2). This
well characterized serum inhibits in vitro binding of DBPII to
erythrocytes and the DARC receptor, as well as inhibits invasion
of human erythrocytes by P. vivax parasites [26].
The nine ‘normal binding’ variant residues tested for sensitivity
to anti-DBP antibody inhibition showed intermediate levels of
inhibition between the naturally occurring residues, N and K, with
the exception of T (Fig. 2). Three variants (T, G, and A) were not
significantly different from naturally occurring variant N (p.0.05),
but were significantly different from naturally occurring variant K
(p,0.05). Five variants (E, Q, S, D and H) were significantly
different from both N and K (p,0.05). Variant R was significantly
different from N (p,0.05), but was not significantly different from
naturally occurring residue K (p.0.05).
The presence of certain polymorphic residues in natural isolates
may be affected by amino acid frequencies. Therefore, amino acid
frequencies for the residues in the ‘normal binding’ variants were
determined from a total of 421 P. vivax coding sequences (with a
total of 295609 residues) (Table 2) [27]. Frequencies of these
amino acids were also determined for the Sal I PvDBP coding
sequence (with a total of 1070 residues) (Table 2). In the larger
dataset, K, E, S, A and N were the most abundant residues. In the
Sal I PvDBP data set K, N, S, D and E were the most abundant
residues. Table 2 also includes the log odds score for substitution of
each amino acid for N in a membrane protein [28]. Positive scores
imply a biochemically favorable substitution, while negative scores
imply a disfavored substitution. Variants are listed in decreasing
order of their inhibition ratio (Fig. 2).
A bias in codon usage for residue 417 may also affect amino
acid substitutions. The codons for variant R that has a binding
phenotype significantly different from naturally occurring residue
N( p ,0.05) but not from naturally occurring residue K (p.0.05),
were analyzed (Table 3). Mutation of residue 417 from N to K
requires a single base change. In contrast, mutation of residue 417
from N to R requires a double or triple base change of the amino
acid codon.
Discussion
Vaccine development against malaria has achieved limited
success so far. A number of challenges need to be overcome in
designing a highly effective vaccine, especially the challenge of
strain-specific immunity. Some antigens like the P. vivax DBP offer
the potential of vulnerable epitopes associated with functionally
sensitive motifs required for receptor recognition. However, the
large number and diversity of polymorphisms found in the regions
of the DBP necessary for ligand recognition and binding suggest
that the parasite is very capable of adapting to evade any
inhibitory host immune response [14–16,29–31].
Consistent with this possibility is the previous work that
demonstrated that strain-specific antibody inhibition can be
mediated by polymorphic residues found in a linked haplotype
Table 1. Association of polymorphisms N417K, W437R and I503K in 292 PvDBP isolates.
Number of Isolates
(% Frequency) with 417K with 437R with 503K with either
417K 132 (45.2%)
a — 125 (94.7%)
b 93 (70.5%)
b 127 (96.2%)
b
437R 146 (50.0%)
a 125 (85.6%)
c — 106 (72.6%)
c 140 (95.9%)
c
503K 145 (49.7%)
a 93 (64.1%)
d 106 (73.1%)
d — 108 (74.5%)
d
a% frequency determined from total of 292 isolates.
b% frequency determined from number of 417K isolates.
c% frequency determined from number of 437R isolates.
d% frequency determined from number of 503K isolates.
doi:10.1371/journal.pone.0020192.t001
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this strain-specific immunity and its importance in binding to
DARC. We updated our previous linked haplotype data by
examining 292 DBP sequences to determine the association of
polymorphisms at the 417, 437 and 503 sites (Table 1). Although
the linkage between these three residues is substantial, we chose to
focus on the single amino acid change at residue 417 separately
from the other polymorphisms for the following reasons. Firstly,
through modeling based on the crystal structure of homologous P.
knowlesi a DBL we found that residue 417 is located adjacent to a
motif identified in two separate studies as important for
recognition of the erythrocyte receptor [24,25,32]. Secondly,
analysis of field isolates indicated that only amino acids N and K
are found at residue 417 (Table 1). We hypothesized that multiple
polymorphisms at this site must be limited by other factors,
possibly including both functional constraints and/or the pressure
of immune selection.
Binding analysis of variant constructs representative of all 20
amino acid possibilities indicates a functional constraint for nine of
the non-naturally occurring residues (Fig. 1), indicating that a single
amino acid substitution can drastically alter the ability of PvDBPII
to bind to the human erythrocyte. The poor erythrocyte binding
properties of these amino acid substitutions would seem to be
sufficienttoprecludetheiroccurrenceonthiscriticalparasiteligand.
We performed inhibition analysis on the remaining eleven
constructs using antisera raised against the Sal I P. vivax strain
containing N417 [26]. A number of residues were significantly
different from N in their inhibition phenotype including E, Q, S,
D, H, R and K. The two naturally occurring amino acids N and K
have the most extreme antigenic differences (Fig. 2).
We calculated amino acid frequencies of the residues in the
‘normal binding’ variants to determine if their scarcity might
suggest a possible explanation for their absence in natural isolates
(Table 2). Although, amino acid frequency may explain the
absence of a few of these polymorphic variants (for example, H or
Q), it is not adequate to explain the absence of other residues such
as E, S or D. Residues E, S and D are among the most frequently
occurring residues in P. vivax CDS (Table 2), have positive log odds
scores for substitution for N (Table 2), display binding phenotypes
intermediate to or greater than the two naturally occurring
residues (Fig. 1) and are significantly different antigenically from N
and K (p,0.05) (Fig. 2) and yet they are absent in natural isolates.
One non-naturally occurring residue (R) was significantly
different in its inhibition phenotype from N (p,0.05), but not
from K (p.0.05). We examined this residue further to try to
determine its absence from natural isolates. The much lower
frequency at which this amino acid appears in P. vivax CDS may
partially explain its absence in natural isolates (Table 2). In
addition, analysis of the nucleotide codons that encode for this
amino acid suggests a genetic explanation (Table 3). Although the
change from N to R would result in a significant change in
antigenicity, it would require a mutation of two or three nucleotide
bases. The change from N to K, the two naturally occurring
residues, results in the most extreme alteration of antigenic
character and is also the simplest to achieve with a single
nucleotide change.
In conclusion, these data demonstrate the impact a single amino
acid substitution can have on both the ability of the PvDBPII to
bind to human erythrocytes and the antigenic character of this
vital invasion protein. In addition, these data provide a partial
Figure 1. Percentage erythrocyte binding to DBP variants containing single amino acid substitutions at the 417 site. Binding is shown
as a percentage compared to the naturally occurring variant N. All constructs are on a Sal I strain background. Polar residues are shown in black.
Nonpolar residues are shown in gray. 1 indicates naturally occurring variant containing N or K at the 417 site. * indicates DBP variants which have
significantly lower binding than one or both of the naturally occurring residues (N and K) (p,0.05). Statistical differences were analyzed using a 1-way
analysis of variance (ANOVA) and a Tukey’s posttest.
doi:10.1371/journal.pone.0020192.g001
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417. A number of residues are eliminated from natural isolates
because of functional constraints in their ability to bind to the red
blood cell receptor. Other residues bind to erythrocytes in a
similar fashion to the naturally occurring variants, but are not
antigenically distinct from naturally occurring residue N, so there
may be a lack of positive immune selection driving their
appearance in natural isolates. Residue R, like naturally
Figure 2. Inhibition of binding to DBP variants containing single amino acid substitutions at the 417 site. Sera raised against Sal I DBP
(containing N417) was tested for its inhibitory efficacy against variant DBP forms with single amino acid changes created on a Sal I strain background
using site-directed mutagenesis. Inhibition ratios were calculated by dividing the percentage inhibition against the variant DBP by the percentage
inhibition against the Sal I control DBP.
a DBP variants which were not significantly different from the Sal I (N) control (p.0.05).
b DBP variants which
were significantly different from both N and K (p,0.05).
c DBP variants which were significantly different from N (p,0.05), but not significantly
different from K (p.0.05). Statistical differences were calculated using a Dunn’s multiple comparisons t-test with a Bonferroni correction for multiple
comparisons.
doi:10.1371/journal.pone.0020192.g002
Table 2. Amino acid frequency in 421 P. vivax CDS and Sal I DBP CDS.
Amino Acid
a
Frequency (%) in 421
P. vivax CDS
b [27]
Frequency (%) in the
Sal I DBP CDS
% Binding relative
to N
Log Odds Score for
substitution for N
c
T 5.27 6.36 52 1
N 6.76 9.53 100 –
G 5.64 6.64 53 22
A 6.80 5.14 64 21
E 8.86 7.66 89 1
Q 3.54 2.71 74 3
S 7.07 9.07 87 2
D 5.48 8.13 125 6
H 1.72 1.68 69 3
R 2.74 4.39 73 2
K 10.51 9.91 81 5
aResidues are shown in decreasing order of their inhibition ratios (See Fig. 2). Naturally occurring residues are in bold and italic.
bCodon usage information can be viewed at http://www.kazusa.or.jp/e/resources/database.html.
cLog odds scores are shown for substitution of N in a membrane protein [28].
doi:10.1371/journal.pone.0020192.t002
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character as compared to residue N, but is a less abundant
residue in P. vivax and is genetically more difficult to achieve
spontaneously. Examination of the codons for these amino acids
indicates that K is the simplest change to achieve with a single
nucleotide substitution necessary to alter the codon. Other factors
that may affect the absence of multiple polymorphisms at this site
include the possibility that the partially linked residues at site 437
and 503 limit the appearance of certain residues at site 417. To
our knowledge, this is the first exhaustive work of this kind to
examine the impact of substitutions at a single residue on binding
and antigenic character. These data provide experimental
support for the hypothesis that positive immune selection pressure
plays a role in the appearance of polymorphisms in functionally
important residues of P. vivax DBP.
Methods
pEGFP-DBPII constructs & site-directed mutagenesis
Salvador I (Sal I) DBPII was cloned into the pEGFP-N1
plasmid with flanking signal sequences from the herpes simplex
virus glycoprotein D1 allowing expression of a GFP fusion
protein on the surface of transiently transfected COS7 cells
(American Type Culture Collection, Manassas, VA). Mutagen-
esis to create a panel of N417 variants was performed using the
Stratagene Quickchange mutagenesis kit (Stratagene, La Jolla,
CA) as previously described [12,23,33,34]. The pEGFP-DBPII
plasmid containing DBPII cloned from the Sal I strain of P. vivax
(containing N at the 417 location) was used as the parent
template. Single residue changes were performed at the 417 site
to create a panel of variants representative of all 20 amino acids
all on the same genetic Sal I background. Recombinant plasmid
DNA was purified using an endotoxin-free plasmid DNA
purification system (Qiagen, Valencia, CA).
COS7 cell binding & inhibition assays
COS7 (green monkey kidney epithelial) cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM, Sigma, St. Louis,
MO) containing 10% fetal bovine sera (FBS). Only cells between
the passage numbers of 5 and 20 were used for binding and
inhibition assays.
COS7 cells were plated in 24-well plates at a density of
35,000 cells per well and were transiently transfected with
endotoxin-free pEGFP-DBPII DNA using Lipofectamine or
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Forty-two hours post-transfection,
the transfected COS7 cells were incubated with DARC-positive
human erythrocytes for 2 hours (2.5610
7 cells/well, previously
washed three times with incomplete DMEM). Wells were
washed three times with PBS to remove nonadherent erythro-
cytes and binding was scored by counting the number of rosettes
per 30 fields of view at 2006 magnification. GFP surface
expression was observed to be consistent between all constructs
suggesting comparable expression levels. Inhibition assays were
carried out in the same manner except that transfected COS7
cells were preincubated for 1 hour at 37uC, 5% CO2 with
antiserum diluted in incomplete DMEM prior to addition of the
erythrocyte suspension. Antiserum against recombinant Sal I
DBPII was produced as previously described [26]. Results from
binding assays are shown as a percentage compared to the
control (containing N at the 417 site). Percentage inhibition was
calculated for each sample by comparing binding in the
presence and absence of serum. A normalized inhibition ratio
was calculated for each sample by dividing the percentage
inhibition of the experimental sample by the percentage
inhibition of the control sample. All binding experiments were
carried out on at least two different clones for each sample and
tested at least three times in triplicate. Inhibition experiments
were carried out at least three times in triplicate.
Analysis of PvDBPII sequences
All available PvDBPII sequences in the NCBI Protein Database
were downloaded on 03/26/2010 and aligned using ClustalW. A
total of 292 sequences were examined at residues 417, 437 and
503 to determine whether polymorphisms at these sites were
linked.
Modeling & statistical analysis
Modeling was done using the MacPymol Molecular Graphics
System (DeLano Scientific LLC, San Carlos, CA, USA) and
SWISS-MODEL (http://swissmodel.expasy.org/SWISS-MODEL.
html)[35,36]. Statistical analyses were performed using the Prism
4 program (GraphPad Software, La Jolla, CA) and the SAS 9.2
program (Cary, NC, USA released 2008). For binding assays,
t h er e s u l t sa r es h o w na sap e r c e n t a g eo ft h er e f e r e n c er e s i d u eN .
The percentages were analyzed using a 1-way analysis of
variance (ANOVA) and a Tukey’s posttest. Residues with
binding phenotypes significantly lower than the two naturally
occurring residues (N and K) (p-value#0.05) were excluded
from inhibition analysis. For inhibition assays, an inhibition
ratio was determined by dividing the mean percentage of each
residue by the mean percentage of the reference residue N to
normalize the data. To determine whether variant residues were
significantly different in their inhibition phenotypes from the
natural occurring residues (N and K), a Dunn’s multiple
comparisons t-test was performed with a Bonferroni correction
for multiple comparisons. Differences from the multiple
comparisons test were found to be statistically significant at a
p-value of 0.05 or less.
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Table 3. Analysis of codons required to alter N to K or R.
Mutation
Codons
(p) indicates
preferred codon
Number of nucleotides
required for change
NRK AATRAAA
AACRAAG
1
NRR AATRAGA (p)
AACRAGG (p)
AATRCGT
AACRCGC
AATRCGA
AACRCGG
2
2
3
doi:10.1371/journal.pone.0020192.t003
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